Centauri Therapeutics
Health
· Headquartered in United Kingdom 🇬🇧
Website
HQ Country
🇬🇧 United Kingdom
LinkedIn
Careers
No public jobs page
Track Centauri Therapeutics
— get Health deals in free daily digest
Overview
Centauri Therapeutics, a UK-based immunotherapy company, has raised £6 million in a Series A extension led by the AMR Action Fund, bringing total Series A funding to £30 million. The funds will be used to complete Phase I clinical studies for ctx-187, a broad-spectrum antimicrobial targeting multidrug-resistant gram-negative bacteria, and to prepare for Phase II trials. The AMR Action Fund aims to support the advancement of ctx-187 through key safety data generation.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Investors: AMR Action Fund
Centauri Therapeutics, a UK-based immunotherapy company, has raised £6 million in a Series A extension led by the AMR Action Fund, bringing total Series A funding to £30 million. The funds will be used to complete Phase I clinical studies for ctx-187, a broad-spectrum antimicrobial targeting multidrug-resistant gram-negative bacteria, and to prepare for Phase II trials. The AMR Action Fund aims to support the advancement of ctx-187 through key safety data generation.
More Health Deals
Market Map
View thousands of companies by category in our market map:
